FIMECS Presents at Virtual Symposium: Targeted Protein Degradation & PROTAC
News release Download PDF
Kanagawa, Japan, 14 Feb 2021 – FIMECS, Inc. (“FIMECS”), a private biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Kanae Gamo, Ph.D., Chief Scientific Officer of FIMECS, will make a presentation at the Virtual Symposium:Targeted Protein Degradation & PROTAC (16-17 February, 2021, Virtual Symposium). A keynote address, “Discovery of Degraders Targeting Pseudokinase IRAK-M for Cancer Immunotherapy” will be scheduled on 16 February, 2021 at 9:30am GMT (UTC+0), which focused on our IRAK-M degrader program.
For more information:
About FIMECS, Inc.
FIMECS, Inc. is developing a new class of drugs based on targeted protein degradation for the currently ‘undruggable’ targets in immuno-oncology and oncology areas. The company became able to discover drug candidates for inducing the degradation of disease-relevant targeted proteins by integrating proprietary E3 ligase binders and RaPPIDS™ platform. This drug discovery platform will help providing drugs to the patients all over the world through various internal and collaboration projects.
# # #
FIMECS, Inc. Media and Investor Contact:
26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan